BIAF: יחס מחיר להכנסות bioAffinity Technologies Inc.

The market capitalization-to-revenue ratio for bioAffinity Technologies (BIAF) demonstrates volatility, where the value of 0.80 corresponds to the current metric, correlating with geopolitical barriers in test exports. Business stability is based on the integration of non-invasive diagnostics into government protocols, ensuring the sale of reagents. The efficiency of the operating model is complemented by a streamlined express delivery system for kits to clinics, eliminating supply chain disruptions.

Investors are assessing the potential of bioAffinity Technologies (BIAF) through the ratio of market capitalization to annual revenue, which determines the value of each dollar of sales. By analyzing the price/sales multiple of bioAffinity Technologies (BIAF), one can understand to what extent the market is pricing in the success of non-invasive lung cancer screening for high-risk groups. Low indicator values coupled with stagnant margins may signal a value trap, neutralizing the attractiveness of scaling the TAM.